Diet in Inflammatory Bowel Disease has become a hot topic in recent years, pushed forward by advances in our understanding of the microbiome and the promise of nutrition as therapy, particularly in Crohn’s Disease. One of the most important questions in clinic (and yet the hardest to answer) remains “What can I eat?” or variations of the same. The reason this question is so difficult to answer is the enormous complexity in how diet overlays IBD and also the lack of high-quality scientific studies addressing this specific problem.
Two new members joined the N-ECCO Committee in February 2024: Maria de Jong from the Netherlands and Cathy Walsh from Ireland. We all share the same mission: promoting IBD nursing in Europe, rolling out educational and research programmes, and developing patient care and education. We are looking forward to working together, and here Maria and Cathy introduce themselves and their aims while on the committee.
I am delighted to share some exciting updates regarding our e-Learning platform. As we embrace the vibrant seasons of spring and summer, I encourage you to take advantage of the latest content we have recently added to the e-Library, including the latest Abstracts and Presentations from the ECCO’24 Congress.
Change is the engine that propels scientific progress, and within this dynamic, committees evolve. As members transition, embracing fresh perspectives, the spirit of innovation flourishes, shaping the path ahead. Amidst this journey, EpiCom is pleased to introduce Paul Henderson while bidding farewell to Julien Kirchgesner.
During the last ECCO’24 Congress in Stockholm, the ECCO Governing Board announced the new strategy REACH. The REACH strategy is the acronym of five clear goals to shape the current and future ECCO activities for the next years, better defining and expanding ECCO global mission to improve the care for all IBD patients.
The first ECCO Global Grant was awarded at ECCO'24 to an international group leading a fascinating prospective study across Sub-Saharan Africa1. The study is focusing on IBD genetics in the region and is being led by Professor Nick Croft and Dr. Phoebe Hodges from Queen Mary University of London, Professor Paul Kelly and colleagues from the Tropical Gastroenterology and Nutrition Group, University of Zambia and Professor McGovern and his group at Cedars-Sinai, Los Angeles. I had the privilege of discussing aspects of the study with members of the study consortium.
For this Y-ECCO Interview Corner we met with Shaji Sebastian, who is known to everyone as Seb, on the Friday of the ECCO Congress. Seb has had a long association with ECCO. He is the outgoing Chair of ClinCom and was elected as Treasurer of ECCO at this year’s General Assembly. He is a consultant in Hull in the North of England, having got there through a somewhat circuitous route, as we will hear...
The SONIC trial yielded seminal findings showing that the combination of infliximab and azathioprine is more effective than either treatment alone for the maintenance of remission in patients with Crohn’s Disease (CD) [1]. In recent years, despite the availability of an increasing number of biologics and small molecules to treat CD, a ceiling of therapeutic efficacy has been reached [2]. Therefore, there has been a resurgence of interest in whether this therapeutic ceiling “effect” can be overcome with new treatment combinations. In the EXPLORER study, the efficacy and safety of triple combination therapy was assessed using two biologics with different modes of action in association with methotrexate for the treatment of CD.
Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: Results of the Constellation Study
Despite an expanding therapeutic arsenal, a considerable proportion of patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) fail to achieve or sustain therapeutic responses [1, 2]. Mechanisms contributing to this failure, particularly with respect to biologic therapy, are only partially understood [3]. Uncovering the mechanisms behind loss of response may help to enhance the efficacy of existing treatment options or to develop alternative options for the future.
Some investigations have noted an association between obesity, high intra-abdominal visceral adipose tissue (IA-VAT) mass and unfavourable outcomes in individuals with Inflammatory Bowel Disease (IBD). However, these observations have been constrained by their methodology and have to date focused only on patients having treatment with anti-tumour necrosis factor alpha (anti-TNF-α) agents [4–6], limiting their scope.
The Constellation Study by Yarur and colleagues aimed to investigate the relationship between IA-VAT in patients with IBD and the response to biologic drugs with multiple different mechanisms of action.
Patients will often ask, “What causes Inflammatory Bowel Disease?” Frustratingly, we remain unable to answer this seemingly simple question, beyond the often-quoted paradigm that unknown environmental factors trigger inflammation in genetically susceptible individuals. Although our understanding of the immune response in IBD has reached phenomenally detailed levels of resolution, the nature and identity of the initial environmental triggers of IBD have continued to remain a mystery. The strong relationship between socioeconomic development and IBD incidence is tantalising evidence of a definable environmental toxin and various substances such as processed food additives have recently been highlighted as potential suspects [1]. However, searching for the causative agent is like looking for a needle in a haystack as the candidate list includes literally every small molecule in existence!
Hannah Gordon
Richard Hansen
Maria de Jong
Cathy Walsh
Pascal Juillerat 
Murat Toruner
Julien Kirchgesner
Robin Dart
